

Important Safety Information for Patients Receiving

Columvi (glofitamab)

Patient Card



- Please carry this card with you at all times while you are receiving Columvi (glofitamab).
- Show this card to any healthcare professional involved in your care.
- Please read this material along with the Patient Information Leaflet supplied with this medicine before taking this medicine.
- Talk to your healthcare professional if you have any questions.



Patient / Caregiver's Contact

Patient's name and contact: _____

Date of Columvi (glofitamab) initiation: _____

Caregiver's name: _____

Caregiver's phone number: _____

Prescribing Doctor's Contact



Prescribing Doctor's name: _____

Prescribing Doctor's phone number: _____

For more information about Columvi (glofitamab), please refer to the Local Prescribing Information (PI). Please report any side effects to Roche Patient Safety at hong_kong.drug_safety@roche.com. By reporting side effects, you can help to provide more information on the safety of this medicine.

Information for the Patient/Caregiver

Contact your Doctor or get emergency help **right away** if you have **any** of these symptoms:

- | | | |
|-----------------------------------|----------------------------------|--------------------------------------|
| ■ Fever (100.4°F /38°C or higher) | ■ Rash | ■ Sleepiness |
| ■ Fast heartbeat | ■ Shortness of breath | ■ Feeling less alert |
| ■ Chills | ■ Feeling dizzy or lightheaded | ■ Seizures |
| ■ Nausea | ■ Being confused / disorientated | ■ Difficulty writing and/or speaking |
| ■ Headache | | |

Experiencing any of these symptoms could be due to **cytokine release syndrome or neurotoxicity syndrome**, which requires immediate evaluation by a Doctor.

Cytokine Release Syndrome

- An exaggerated inflammatory condition associated with medicines that stimulate T cells, characterised by fever and impairment to multiple organs in the body.
- May be caused by receiving glofitamab and is more likely to occur during Cycle 1 after glofitamab is given.
- Close monitoring is needed. Before each infusion, you may be given medicines which help reduce possible side effects of cytokine release syndrome.

Information for the Treating Doctor

This patient has received Columvi (glofitamab) - **which may cause Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).**

- Evaluate the patient immediately and treat symptoms.
- If CRS or ICANS is suspected, please refer to the Prescribing Information of glofitamab for comprehensive instructions on CRS and ICANS management.
- **Contact the prescribing doctor** when possible - they may need to modify the next infusion of glofitamab.